Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimiter S Dimitrov

Showing results (271-280 of 284) with videos related to

Pageof 29
Sort By:
Nature|November 8, 2023
Retraction Note: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARsMark Yarmarkovich, Quinlen F Marshall, John M Warrington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2019
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain TumorsRobbie G Majzner, Johanna L Theruvath, Anandani Nellan, et al.
Cancer Cell|September 13, 2017
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk NeuroblastomaKristopher R Bosse, Pichai Raman, Zhongyu Zhu, et al.
Cell Reports. Medicine|May 9, 2024
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcomaMeijie Tian, Jun S Wei, Nityashree Shivaprasad, et al.
Cell Reports|November 29, 2023
Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capabilityYang Feng, Jaewon Lee, Liping Yang, et al.
Cell Reports. Medicine|September 29, 2023
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcomaMeijie Tian, Jun S Wei, Nityashree Shivaprasad, et al.
Iscience|July 25, 2022
Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domainsChuan Chen, James W Saville, Michelle M Marti, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2022
Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH DomainsChuan Chen, James W Saville, Michelle M Marti, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 5, 2025
Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineeringYunji Liao, Hang Ma, Zhenyu Wang, et al.
Cancer Discovery|May 22, 2021
Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing SarcomaHai-Feng Zhang, Christopher S Hughes, Wei Li, et al.
Pageof 29

Showing results (271-280 of 284) with videos related to

Sort By:
Pageof 29
Nature|November 8, 2023
Retraction Note: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARsMark Yarmarkovich, Quinlen F Marshall, John M Warrington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2019
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain TumorsRobbie G Majzner, Johanna L Theruvath, Anandani Nellan, et al.
Cancer Cell|September 13, 2017
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk NeuroblastomaKristopher R Bosse, Pichai Raman, Zhongyu Zhu, et al.
Cell Reports. Medicine|May 9, 2024
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcomaMeijie Tian, Jun S Wei, Nityashree Shivaprasad, et al.
Cell Reports|November 29, 2023
Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capabilityYang Feng, Jaewon Lee, Liping Yang, et al.
Cell Reports. Medicine|September 29, 2023
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcomaMeijie Tian, Jun S Wei, Nityashree Shivaprasad, et al.
Iscience|July 25, 2022
Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domainsChuan Chen, James W Saville, Michelle M Marti, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2022
Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH DomainsChuan Chen, James W Saville, Michelle M Marti, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 5, 2025
Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineeringYunji Liao, Hang Ma, Zhenyu Wang, et al.
Cancer Discovery|May 22, 2021
Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing SarcomaHai-Feng Zhang, Christopher S Hughes, Wei Li, et al.
Pageof 29